# ANCHOR CRC (NCT03693170)

> Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

No report yet. It can be ordered.

- Drugs tested: encorafenib plus binimetinib plus cetuximab
- Indication: previously untreated BRAF V600E-mutant metastatic colorectal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03693170
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Pierre Fabre Medicament
- Conditions: BRAF V600E-mutant Metastatic Colorectal Cancer
- Interventions: encorafenib; Binimetinib; Cetuximab
- Enrollment: 95
- Primary outcome: Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments

## Indexed commentary on ANCHOR CRC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- Podcasts: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=anchor-crc-nct03693170

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03693170", "email": "<work email>"}; the inbox owner confirms by the emailed link.